SCID screening false positives: avoiding diagnostic panic

The screening test is designed to identify babies who may have too few newly formed T cells, and it deliberately favors sensitivity over specificity. As a result, many infants with a low T-cell receptor excision circle, or TREC, result will need further assessment even though they do not have SCID.

The immediate task is therefore twofold: protect the infant while the immune evaluation is underway, and move efficiently from the screening signal to a confirmed clinical interpretation. For families searching for the newborn SCID screening false positive next steps, this distinction matters. A result can be abnormal because of true SCID, another form of T-cell lymphopenia, a congenital syndrome, or a temporary effect of prematurity and intensive neonatal care.

Understanding what the TREC assay is actually measuring

TREC screening is a molecular test performed on the same type of dried blood spot used for other newborn screening programs. It does not directly count mature T cells and it does not identify a specific genetic mutation. Instead, it detects small circular DNA fragments created during T-cell receptor rearrangement in the thymus.

A low TREC level suggests that the infant may not be producing an expected number of new T cells. That signal can occur in SCID, where cellular immunity is profoundly impaired, but it can also reflect less severe or secondary conditions. The assay is best understood as an early warning system within a broader diagnostic pathway rather than as a stand-alone SCID test.

This is why an abnormal TREC screen must be followed by laboratory and clinical assessment. The screen answers a narrow question: whether the amount of T-cell production appears lower than expected for the screening laboratory’s reference range. It does not answer the larger questions that determine diagnosis and management:

• How many T cells are present in the infant’s blood?
• Are those cells naïve, recent thymic emigrants, or more mature memory cells?
• Are B cells and natural killer cells present in expected proportions?
• Are the lymphocytes functioning normally?
• Is there a congenital syndrome, medication exposure, illness, or another explanation for the result?
• Does the infant require immediate protective measures and evaluation for curative treatment?

Approximately 1 in 20,000 newborns may have a low T-cell result on screening, while the rate of confirmed SCID is closer to 1 in 58,000 infants. Those figures illustrate the central clinical point: an abnormal screen is more common than the disease it is intended to detect.

A low TREC result is a signal to accelerate the immune evaluation—not a verdict that the infant has SCID.

TREC screening became a statewide program in Wisconsin in 2008 and was widely adopted across all U.S. states by 2017. Its value lies in identifying affected infants before serious infections occur, when treatment decisions can be made proactively. That benefit depends on a prompt and carefully staged follow-up process.

Why premature and NICU infants generate more abnormal results

The most important context for interpreting a TREC result is the infant’s clinical history at the time the specimen was collected. Prematurity, low birth weight, antenatal corticosteroid exposure, and hospitalization in a neonatal intensive care unit can all influence the result.

The fetal and neonatal immune systems are still developing, and T-cell production changes with gestational age. A premature infant may therefore have a lower TREC level than a term infant without having SCID. A difficult neonatal course can add further variables, including medical treatment, physiologic stress, transfusions, and temporary changes in blood cell distribution.

In California reports, NICU infants represented about 9% of births but accounted for 47% of abnormal TREC results. That difference does not mean NICU infants are likely to have SCID. It shows that screening performance is strongly shaped by the population being tested. Premature and low-birth-weight infants have been reported to experience false-positive screening rates approximately 18 to 30 times higher than term infants.

This is also why many newborn screening programs use a separate procedure for premature or NICU infants. Rather than moving immediately from a low TREC result to a liquid blood draw in every case, the protocol may require a second dried blood spot specimen after a defined interval, commonly at around 2 weeks or 28 days, depending on the infant’s gestational age, weight, and the state or laboratory protocol.

The timing is not arbitrary. The purpose is to allow additional immune maturation and to determine whether the TREC level remains abnormal. A repeat dried blood spot can be useful when the initial result is likely to have been affected by prematurity, but it should not delay specialist assessment when the result is markedly abnormal or the infant has clinical features that raise concern.

What the first result does—and does not—tell you

A positive or unacceptable TREC screen can mean several different things:

The clinical presentation remains important even when the baby appears well. SCID can be present before infections develop, and a healthy appearance does not reliably exclude a serious immune disorder. At the same time, a well-appearing premature infant with a mildly low TREC result is not automatically experiencing an emergency equivalent to confirmed SCID. The management pathway must hold both truths at once: do not dismiss the screen, and do not convert it into a diagnosis before confirmatory evidence exists.

The abnormal TREC screen next steps

The standard next step after an abnormal screen is a complete blood count with differential and a lymphocyte subset analysis by flow cytometry. The newborn screening laboratory or the infant’s clinician may also arrange repeat dried blood spot testing, particularly for premature or NICU infants.

1. Review the screening result and neonatal history

The immunology team will want the exact screening category, the infant’s gestational age and birth weight, the date and type of specimen, and whether the sample was obtained before or after major neonatal interventions. The result may be described as low, abnormal, or unacceptable, and those terms do not always carry the same clinical meaning.

The team will also review:

• NICU admission and the reason for hospitalization
• Antenatal corticosteroid exposure
• Blood transfusions or other blood products
• Current medications and major neonatal illnesses
• Physical findings that could suggest a congenital syndrome
• Any fever, respiratory symptoms, diarrhea, thrush, or other signs of infection
• Family history of early childhood infections, unexplained infant deaths, or known immune disorders

This history helps determine whether the appropriate next move is immediate flow cytometry, a repeat dried blood spot, or both in parallel.

2. Perform a CBC with differential

The CBC provides an initial overview of white blood cell numbers, including the absolute lymphocyte count. It is not sufficient to confirm or exclude SCID, but it helps identify whether the infant has a broader or more pronounced lymphopenia.

A normal total white blood cell count cannot reassure us that T-cell immunity is normal. Conversely, a low lymphocyte count may have several causes and must be interpreted in relation to gestational age, clinical condition, and the flow cytometry findings. Pediatric reference ranges are not interchangeable with adult ranges, and extremely premature infants may not fit neatly into a single standardized interval.

3. Use flow cytometry to define the lymphocyte populations

Flow cytometry measures the major lymphocyte subsets in a blood sample. In this setting, the analysis generally includes T cells, B cells, and natural killer cells, with additional markers that help distinguish naïve and memory T-cell populations.

This is the key transition from a screening signal to an immune phenotype. The pattern can help clinicians determine whether the infant has:

• Severe reduction in T cells consistent with a high-risk cellular immune deficiency
• T cells present in low numbers but not absent
• A pattern suggesting secondary or transient lymphopenia
• A combined reduction affecting more than one lymphocyte compartment
• A preserved immune profile in which the initial low TREC result may have been related to prematurity or specimen timing

A threshold of fewer than 300 autologous T cells per microliter is characteristic of persistent SCID or severe lymphopenia requiring urgent curative evaluation. However, no single number should be interpreted outside the complete flow cytometry report, clinical presentation, and specialist assessment. The quality of the sample, transfusion history, age, and laboratory methods all affect interpretation.

If flow cytometry shows a concerning pattern, the team may proceed rapidly to functional testing, genetic sequencing, and evaluation for hematopoietic stem cell transplantation or another disease-specific treatment pathway. If the result is reassuring but not fully definitive, repeat testing may be needed rather than immediate discharge from follow-up.

4. Consider genetic and functional testing when indicated

Genetic sequencing can identify variants associated with SCID and other inherited immunodeficiencies, but it is not a substitute for immune cell enumeration. A genetic result may require careful interpretation because some variants are uncertain, and not every clinically important immune disorder is captured by a single gene panel.

Functional assays may examine how T cells respond to stimulation. Additional tests can be selected according to the immune phenotype, family history, physical examination, and suspected diagnosis. The purpose is not to order every available test; it is to connect the laboratory pattern with the underlying mechanism in the immune cascade.

For some families, genetic counseling is an important part of this stage. If a pathogenic variant is identified, testing may be offered to parents and other relatives, and the result may inform future pregnancy planning or prenatal genetic screening. These conversations should be handled with appropriate counseling, because a genetic finding can affect more than the infant’s immediate treatment plan.

Protecting the infant while confirmation is pending

When the TREC screen is abnormal, precautionary care often begins before the diagnosis is settled. These measures are not a declaration that SCID has been confirmed. They are a way to reduce avoidable exposure during a period when the infant’s cellular immunity is not yet adequately characterized.

Depending on the screening result and the immunologist’s recommendations, families may be advised to:

• Avoid live vaccines, including rotavirus vaccine, until the immune evaluation is complete and a specialist confirms that vaccination is appropriate.
• Limit contact with people who are ill and follow the clinical team’s infection-control guidance.
• Avoid crowded environments when the infant’s risk profile warrants additional protection.
• Ensure that blood products, if needed, are irradiated and leukoreduced, with additional specifications according to the treating center.
• Contact the clinical team promptly for fever, respiratory symptoms, persistent diarrhea, poor feeding, unusual rash, or other signs of illness.
• Discuss breastfeeding and maternal medications with the medical team if a significant immune deficiency remains under consideration.

The rotavirus decision deserves particular care. Rotavirus vaccine is live, so it should not be given while an abnormal TREC result is awaiting confirmatory evaluation unless the responsible immunology team has determined that the infant’s immune function is adequate. Families should not make this decision based on a general vaccine schedule alone; the result needs to be communicated to the pediatrician and immunologist promptly.

The same principle applies to visitors, siblings, and routine care. The goal is proportionate protection, not unnecessary isolation without medical direction. An immunologist can explain which precautions are temporary and which remain necessary if testing confirms a significant immune disorder.

A positive screen can reveal conditions other than SCID

One of the strengths of TREC screening is that it can identify clinically important T-cell lymphopenia beyond classic SCID. The differential diagnosis may include congenital syndromes such as DiGeorge syndrome and CHARGE syndrome, as well as secondary reductions in T-cell numbers.

The clinical presentation may point toward one of these possibilities. Physical examination, cardiac assessment, calcium measurement, hearing evaluation, developmental review, and targeted genetic testing may all become relevant depending on the findings. The infant may not have recurrent infections, because newborn screening often detects the immune problem before that history has had time to develop.

Other explanations can include temporary lymphopenia associated with prematurity or serious illness. In these cases, the immune cell counts may improve as the infant matures or recovers. Improvement is reassuring, but it should be documented through appropriate follow-up rather than assumed from the infant’s appearance.

Why the broader diagnosis matters

The distinction between SCID and other forms of T-cell lymphopenia changes nearly every element of management:

• Infection precautions may be more or less intensive.
• Vaccine planning may follow a different timetable.
• The need for antimicrobial prophylaxis depends on immune function and the final diagnosis.
• Genetic counseling may be relevant even when transplantation is not.
• Cardiac, endocrine, developmental, or other specialty care may be needed for a congenital syndrome.
• The long-term prognosis can range from transient normalization to a severe inherited immunodeficiency requiring curative treatment.

This is why a false-positive SCID test in a newborn is not necessarily a medically meaningless event. The screen may be false positive for SCID but still correctly identify an infant who needs evaluation for another condition. Conversely, a low TREC result in a premature infant may normalize without revealing a lasting immune disorder. Only the follow-up pathway can separate these outcomes.

How clinicians balance urgency with uncertainty

Families often receive an abnormal result before they have had an opportunity to speak with an immunologist. The language used by screening programs can be necessarily cautious: abnormal, positive, urgent follow-up, or possible immune deficiency. These terms are designed to prevent missed diagnoses, but they can sound definitive when read outside their clinical context.

We should interpret the result in layers:

1. The screen has identified a possible reduction in newly produced T cells.

2. The infant’s clinical and neonatal history changes the likelihood of a transient or secondary explanation.

3. CBC and flow cytometry determine the actual lymphocyte pattern.

4. Functional and genetic testing may clarify the mechanism.

5. The final diagnosis determines treatment, vaccination, infection prevention, and follow-up.

This layered interpretation prevents two opposite errors. The first is diagnostic panic: assuming that every abnormal TREC result confirms SCID. The second is false reassurance: assuming that prematurity explains every low result and that no further testing is necessary.

Prematurity raises the likelihood of a false-positive TREC result, but it does not rule out true SCID; the follow-up test is where the distinction is made.

The timing of repeat testing depends on the protocol and the infant’s clinical circumstances. Some programs request a second dried blood spot at 2 weeks or 28 days for premature or NICU infants. Others proceed directly to a blood sample for flow cytometry when the result or clinical history warrants it. There is no single universal timetable that replaces communication with the screening laboratory and pediatric immunology service.

What a reassuring follow-up can mean

If flow cytometry shows appropriate lymphocyte numbers and a healthy distribution of T-cell subsets, the immunologist may conclude that the initial screen was a false positive or reflected a temporary condition. The family may still be asked to complete repeat testing, particularly if the infant was extremely premature, the sample was collected very early, or the initial result was difficult to interpret.

A reassuring result generally allows the care team to return to routine pediatric management, but the exact timing of vaccine decisions and any remaining precautions should come from the clinicians who reviewed the immune evaluation. The infant’s ongoing clinical presentation also remains relevant. New or unusual infections, poor growth, persistent diarrhea, or other concerning symptoms should be assessed even after an initially reassuring screen.

For a baby who is well and whose immune testing normalizes, the long-term outlook is often reassuring. The important point is that reassurance should be based on documented follow-up, not simply on the absence of symptoms during the first weeks of life.

When the result remains abnormal

Persistent or severe T-cell lymphopenia requires a more intensive management pathway. The care team may arrange additional immune function studies, genetic sequencing, infectious disease review, and evaluation at a center experienced in treating severe pediatric immunodeficiency.

If SCID is confirmed, treatment planning is time-sensitive because the best outcomes are associated with protecting the infant from serious infection and proceeding to definitive therapy before preventable infections occur. Hematopoietic stem cell transplantation is a central curative approach for many forms of SCID, although the precise strategy depends on the genetic diagnosis, donor options, infection status, and the expertise of the treating center. Other therapies may be appropriate for particular molecular causes.

For conditions outside classic SCID, management may range from observation with repeat immune testing to prophylactic treatment, immunoglobulin replacement, syndrome-specific care, or transplantation. The laboratory result is therefore the beginning of a diagnostic conversation, not the endpoint.

Finding a clear route through an abnormal screen

The most useful response to an abnormal TREC result is organized follow-up. Ask the newborn screening program or pediatrician which category of result was reported, whether a repeat dried blood spot is required, when flow cytometry should occur, and which precautions apply while testing is pending. Ensure that the result is visible to every clinician involved in the infant’s care, especially before vaccination or a blood transfusion.

For parents, the practical sequence is usually:

1. Confirm that the pediatrician and pediatric immunology team have received the report.

2. Clarify whether the infant needs an immediate blood draw, a repeat dried blood spot, or both.

3. Follow temporary vaccine and infection-control instructions, including avoiding live vaccines until advised otherwise.

4. Bring the infant’s gestational age, birth weight, NICU history, medication list, and transfusion history to the consultation.

5. Ask when the family will receive the CBC, flow cytometry, and any repeat-test results.

6. Request a written plan for fever, illness, visitors, vaccines, and follow-up appointments.

That route protects against delay without labeling the infant prematurely. It also gives families a way to understand why the initial screen may be abnormal even when the baby appears healthy.

A false-positive SCID screen is unsettling because the test is designed to detect a serious disease before symptoms emerge. Yet the same screening system that creates follow-up alarms also creates an opportunity: true SCID and other clinically significant immune disorders can be identified early, when infection prevention and treatment planning have the greatest impact. With prompt flow cytometry, thoughtful interpretation of prematurity and NICU factors, and specialist-led follow-up, most families can move from an alarming screening result toward a clear diagnosis and an appropriate long-term care plan.